Libera Bio develops novel therapeutics utilizing proprietary nanotechnology to deliver biologics across the cell membrane to address previously undruggable intracellular targets in oncology. Their MPN Technology® encapsulates large molecules like antibodies for targeted intracellular delivery within tumor cells. The company partners to advance these breakthrough treatments from preclinical research into clinical development for cancer patients.
Funding
$14.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments struggle to reach intracellular targets, particularly in tumors with mutations like KRAS, leading to poor prognoses and resistance to conventional therapies. Delivering large biologic molecules, such as monoclonal antibodies, directly into cancer cells remains a significant challenge.
Solution
Libera Bio is developing a new class of therapeutics based on its patented Multifunctional Polymeric Nanoparticles (MPN Technology®) to address previously undruggable intracellular cancer targets. The MPN Technology® enables the intracellular delivery of biologics, including monoclonal antibodies, to tumor cells. This approach allows the company to develop new compounds involving intracellular biologics to engage previously undruggable targets. Libera Bio is dedicated to developing treatments addressing intracellular disease targets, with an initial focus on cancer, through independent efforts and strategic collaborations.
Target Audience
The primary target audience includes oncology biopharma partners interested in licensing or co-developing new cancer treatments based on biologics or small molecules, as well as patients with cancers characterized by difficult-to-reach intracellular targets.
Features
- Patented MPN Technology® for intracellular delivery of biologics.
- Enables delivery of monoclonal antibodies (mAbs) and other large molecules.
- Designed for optional co-delivery of small molecule agents.
- Streamlined and scalable platform designed to bridge preclinical research to clinical development.
- Targets tumors with mutations like KRAS.
- Can encapsulate a range of therapeutic payloads, such as antibody fragments/nanobodies, and PROTACs/AbTACs.